Company history

Horiba began in 1945 as a one-man workshop. Horiba Masao, born in 1924 and still reading science at Kyoto Imperial University, opened Horiba Radio Laboratory in a rented house barely three and a half ken wide. Its first line — electrolytic capacitors — went nowhere, and what saved it was a measuring instrument: in 1950 he completed Japan’s first glass-electrode pH meter, rebuilding an instrument that until then had only been imported into something that would survive a Japanese summer. In January 1953 the laboratory was incorporated as Horiba, Ltd. with capital of $2,778 (¥1m), backed by three Kyoto businessmen who stood as guarantors — men Horiba would later call Japan’s first venture capitalists.

The pH meter did more than replace a failed product; it fixed the shape of the company. Develop the sensor in-house, buy in everything around it — that split, learned on the pH meter, carried straight into the infrared gas analyzer that became the second pillar. It also made Horiba a credible partner for a giant: in November 1959 it signed a technical and business alliance with Hitachi under the joint brand “Hitachi–Horiba,” concentrating its own people on developing analytical instruments while manufacturing went to partner plants and sales to Hitachi’s distributor Nissei Sangyo. Masao’s reasoning was plain — a small firm survives by specialising, not by imitating a conglomerate.

In November 1965, months after the head office moved to its present site in Minami-ku, Horiba began selling automotive exhaust-gas analyzers. Nothing about them was new science: the 0.1-second response perfected on a medical breath-gas analyzer transferred directly to exhaust that changes with every driving condition. Horiba exhibited the device as a form of market research, hauled in used engines and invited criticism before committing to volume. Emissions regulation then arrived as a tailwind, and the instrument became standard equipment on production lines. A 1970 paper merger with the former Nihon I Seihin — changing the shares to a ¥50 par value — tidied the register for a stock listing.

In March 1971 Horiba listed on the second section of the Osaka exchange and on the Kyoto exchange, eighteen years after incorporation, on revenue of about ¥4.5 billion. A sales tie-up with Nissei Sangyo followed that September. Then, in quick succession, came the overseas arms: the European office in Germany became Horiba GmbH in 1972, Horiba Instruments opened in the United States in 1973, and a British subsidiary in 1977. For an instrument maker whose customers were carmakers and laboratories, being present where the test benches stood was not optional.

The domestic ladder was climbed in parallel — the second section of the Tokyo exchange in 1974, then the first sections of both Tokyo and Osaka in 1982, eleven years after the first listing. In 1984 Horiba built a crystal plant in Kyoto to make optical crystals in volume, pulling the core component of its gas analyzers back in-house — the same instinct that had produced the pH electrode. Horiba Korea followed in 1988. Europe and America in the 1970s, Asia in the 1980s: by the end of the period a Kyoto instrument maker had the skeleton of a global network, if not yet the scale.

In 1992 Horiba Atsushi, the founder’s eldest son, became president, and the company stopped growing only from within. In June 1996 it bought ABX of France — a world leader in blood-cell counters — on the reasoning that a company already holding the sensing and analytical core could enter global medical diagnostics faster by buying a leader than by building one: the deal delivered a full product line, worldwide distribution and product-planning capability in a single stroke. A Beijing office opened the same year, a Singapore subsidiary in 1997, Instruments SA of France in 1997, and Atago Bussan — later Horiba Jobin Yvon — in 1998, extending the same logic into scientific analysis.

By the late 1990s each borrowed field had become a real business. In semiconductors the subsidiary Stec (now Horiba Stec) held the world’s largest share — about 32% — in mass flow controllers, the devices that meter process gases by mass, supplying Applied Materials and Tokyo Electron. In medicine, Horiba and ABX jointly produced in 1998 the world’s first compact analyzer to measure the inflammation marker CRP and white-cell count together, a hit with clinics and emergency laboratories.

The largest structural move came in 2005, when Horiba Europe acquired Germany’s Schenck Pegasus together with its American, Korean and Japanese affiliates, making Horiba a global force in automotive test systems and setting the five-segment shape — automotive, process & environment, medical, semiconductor, scientific — that would hold for the next two decades. A plant at Biwako in Shiga followed in 2009 to build those test systems in Japan; Cameron International’s process-instruments division in 2013 and Photon Technology International’s fluorescence business in 2014 filled gaps by field; and in 2015 the purchase of MIRA in Britain added vehicle engineering and testing services, completing the automotive line from instrument to service.

In October 2017 Horiba announced that Adachi Masayuki would succeed Horiba Atsushi as president, with Atsushi staying on as chairman and Group CEO: a two-man structure in which the founding family directed the group and a career engineer ran the operating company. Adachi had studied solid-state optics at Ritsumeikan and developed the optical filters at the heart of gas analyzers before running overseas subsidiaries — the first president from outside the family, inheriting rather than rewriting the five-segment, niche-leader strategy. The acquisitions did not stop: FuelCon for fuel-cell testing and Rohm’s micro-blood-testing business in 2018, MANTA Instruments for particle sizing and TOCADERO Analytics for water quality in 2019.

Then the earnings mix turned over. Automotive testing slowed under COVID-19 while semiconductor capital spending surged, and the mass flow controller business Horiba had held quietly for thirty years became the profit engine. FY2020 revenue of ¥187.0 billion and operating profit of ¥19.7 billion gave way to a record FY2021 — ¥224.3 billion and ¥32.0 billion — and then to FY2022 revenue of $2.1B (¥270bn) with ¥45.8 billion of operating profit, clearing the MLMAP2023 mid-term targets a full year early. Adachi has described the result as having grown semiconductor-related business into a second earnings pillar after automobiles.

From 2024 the new mid-term plan re-cut the five segments into three axes — energy & environment, bio & healthcare, and advanced materials & semiconductor — an admission that the old segments no longer described where the money came from. Tethys Instruments and Process Instruments were added in 2023, while the MIRA UGV stake was pared back and finally deconsolidated in 2025. FY2024 revenue reached ¥317.3 billion with ¥48.3 billion of operating profit, and FY2025 ¥333.0 billion with ¥53.0 billion — the company measuring semiconductors now larger than the one that measured engines.